EBA, Safety and Tolerability of Sanfetrinem Cilexetil

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-21

Study Completion Date

2024-08-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the 2-week bactericidal activity, pharmacokinetics, safety and tolerability of sanfetrinem cilexetil in participants with rifampicin-susceptible pulmonary tuberculosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB

NCT01392911

Pulmonary Tuberculosis (TB)

COMPLETED PHASE2

Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults

NCT04493671

Pulmonary Disease Tuberculosis, Pulmonary Tuberculosis +4 more

COMPLETED PHASE1

Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers

NCT02387242

Tuberculosis

SUSPENDED PHASE1

Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults

NCT04890535

Tuberculosis

COMPLETED PHASE1

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)

NCT01215110

Pulmonary Tuberculosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A single-centre, open-label, clinical trial in two stages. Stage 1 will recruit 20 participants followed by a recruitment pause and an interim analysis to determine if sanfetrinem cilexetil has early bactericidal activity (EBA). Should EBA be demonstrated, stage 2 will focus on optimising sanfetrinem cilexetil.

All treatments will be administered orally (PO) on days 1-14. The treatments are:

Stage 1:

* Sanfetrinem cilexetil 1.6 g PO 12-hourly
* Rifampicin 35 mg/kg PO once daily (OD)\*

An interim analysis is planned after stage 1 to review the pharmacokinetics (PK), safety, tolerability and EBA of sanfetrinem cilexetil. Results of stage 1 will determine whether stage 2 should proceed and if any modifications in dose, duration or combinations are required for Stage 2. If deemed possible, a PK-EBA model will be derived using only stage 1 from which clinical trial simulations will be conducted to inform the design of stage 2. If EBA is not demonstrated, the study will be stopped after stage 1.

Stage 2:

* Rifampicin 35 mg/kg po OD\*
* Sanfetrinem cilexetil 2.4 g PO OD

Five of the rifampicin 35 mg/kg arm participants will be recruited in stage 1 and the remainder in stage 2.

Participants on rifampicin will serve as control for the EBA quantitative mycobacteriology.

The study will not be blinded but the mycobacteriology laboratory staff performing the endpoint assays will remain blinded until analysis of the EBA results.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis, Pulmonary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Approximately 51 participants (3 groups of approximately 15 participants receiving IP including replacements in Stage 1) will be enrolled. 26 participants were enrolled in stage 1 and 25 are planned to be enrolled in stage 2. Participants will be between 18 and 65 years old (inclusive), with newly diagnosed, smear or Xpert MTB/RIF-positive, rifampicin susceptible pulmonary TB.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Laboratory personnel are blinded to treatment arm

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sanfetrinem cilexetil 1.6 gram 12 hourly

Sanfetrinem cilexetil 1.6g will be given orally 12 hourly for 14 consecutive days.

Group Type EXPERIMENTAL

Sanfetrinem Cilexetil

Intervention Type DRUG

Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.

Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules

Rifampicin 35 mg/kg once daily

Rifampicin 35 mg/kg will be given orally once daily for 14 consecutive days.

Group Type EXPERIMENTAL

Rifampicin

Intervention Type DRUG

Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.

Sanfetrinem cilexetil 2.4 gram once daily

Sanfetrinem cilexetil 2.4 g will be given orally daily for 14 consecutive days.

Group Type EXPERIMENTAL

Sanfetrinem Cilexetil

Intervention Type DRUG

Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.

Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sanfetrinem Cilexetil

Sanfetrinem cilexetil powder, weighed for dose and administered as a suspension in water.

Amx/CA 250/125 mg tablets Rifampicin 150 mg, 300 mg and 600 mg tablets or capsules

Intervention Type DRUG

Rifampicin

Rifampicin will be administered at a dose of 35 mg/kg once daily for 14 days with or without sanfetrinem cilexetil.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Compound number GV118819 Rifadin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants are required to meet all of the following criteria in order to be randomized.

1. Provide written, informed consent prior to all trial-related procedures.
2. Male or female, aged between 18 and 65 years, inclusive.
3. Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive.
4. Newly diagnosed, previously untreated, rifampicin-susceptible pulmonary TB.
5. A chest X-ray picture taken at screening which, in the opinion of the investigator, is consistent with TB.
6. Sputum positive on direct microscopy for acid-fast bacilli on at least one sputum sample (at least 1+ on the IUATLD/WHO scale) or GeneXpert cycle threshold of medium or high.
7. Ability to produce an adequate volume of sputum as estimated from an overnight sputum collection sample (estimated 10 ml or more).
8. Be of non-childbearing potential or using effective methods of birth control, as defined below:

Non-childbearing potential:

Female participant/ female sexual partner - bilateral oophorectomy

* bilateral tubal ligation
* hysterectomy
* postmenopausal with no menses for at least 12 consecutive months Male participant/ male sexual partner - vasectomy
* bilateral orchidectomy more than three months prior to screening

Effective birth control methods:

1. Participant is not heterosexually active or practicing sexual abstinence
2. Double barrier method which can include a male condom, diaphragm, cervical cap, or female condom (male and female condoms should not be used together); or
3. Barrier method combined with hormone-based contraceptives or an intra-uterine device for the female partner.

Exclusion Criteria

* Participants will be excluded from participation if they fulfil any of the following criteria.

1. Evidence of clinically significant conditions or findings, other than TB, that might compromise safety or the interpretation of trial endpoints, per discretion of the investigator.
2. Poor general condition where any delay in treatment cannot be tolerated per discretion of the investigator.
3. Clinically significant evidence of extrathoracic TB, as judged by the investigator.
4. History of allergy to any of the trial IP/s or related substances i.e. β-lactams and penicillin, as confirmed by the clinical judgement of the investigator.
5. Alcohol or drug abuse, that in the opinion of the investigator, is sufficient to compromise the safety or cooperation of the participant.
6. HIV positive ONLY IF:

* CD4 \< 250cells/mm3
* On ART
7. Participation in other clinical studies with investigational agents within 8 weeks prior to trial start (with the exception of COVID-19 vaccines).
8. Female participant who is pregnant, breast-feeding, or planning to conceive a child within the anticipated period of trial participation. Male participant planning to conceive a child within the anticipated period of participating in the trial.
9. Treatment received with any drug active against M.tb (including but not limited to isoniazid, ethambutol, amikacin, cycloserine, fluoroquinolones, rifabutin, rifampicin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, thioacetazone, capreomycin, thioamides), or with immunosuppressive medications such as TNF-alpha inhibitors within 2 weeks prior to screening, or systemic corticosteroids for more than 7 days within 2 weeks prior to screening.
10. Participants with the following toxicities at screening as defined by the enhanced CTCEA toxicity table

1. creatinine \>1.5 times upper limit of normal \[ULN\];
2. haemoglobin \<8.0 g/dL;
3. platelets \<50x109 cells/L;
4. serum potassium \<3.0 mmol/L;
5. aspartate aminotransferase (AST) ≥3.0 x ULN;
6. alanine aminotransferase (ALT) ≥3.0 x ULN;
7. Total white cell count \<1.5 cells/L
11. For participants undergoing PET/CT, the following are excluded:

1. Participants with diabetes (Type 1 or 2) with point of care HbA1c above 6.5, or random glucose over 11.1 mmol/L.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No